☆ 4.6 Article

Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases

NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION

Volume 24, Issue 9, Pages 2752-2754

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/ndt/gfp166

Keywords

anti-factor H antibodies; haemolytic uraemic syndrome; MCP mutation; varicella

Categories

Transplantation Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

We report two cases of children who presented with haemolytic uraemic syndrome following varicella infection. One of them had a membrane cofactor protein mutation, and the other had anti-factor H antibodies. These observations show that infectious agents such as varicella-zoster virus may be the trigger of haemolytic uraemic syndrome in patients with complement dysregulation.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome

Irene Gomez Delgado, Fernando Corvillo, Pilar Nozal, Emilia Arjona, Alvaro Madrid, Marta Melgosa, Juan Bravo, Agnes Szilagyi, Dorottya Csuka, Nora Veszeli, Zoltan Prohaszka, Pilar Sanchez-Corral

Summary: SP-HUS is a clinically well-known disease that may have a worse prognosis than HUS associated with E. coli infections. Studies suggest that risk variants in the CFH-CFHR3-CFHR1 region could contribute to disease-predisposition to SP-HUS, and transient desialylation of complement FH by the pneumococcal neuraminidase may play a role in disease pathogenesis.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Haemolytic uraemic syndrome

Mini Michael, Arvind Bagga, Sarah E. Sartain, Richard J. H. Smith

Summary: Haemolytic uraemic syndrome (HUS) is a group of diseases that cause thrombotic microangiopathy, characterized by non-immune microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury. The most common cause of HUS discussed in this review is Shiga toxin-producing Escherichia coli HUS. Identifying the trigger of thrombotic microangiopathy is crucial for personalized treatment. Complement-mediated HUS, once associated with high mortality, can now be treated with anti-complement therapies. However, the high cost of these therapies limits their use in low-income countries.

LANCET (2022)

Add to Collection

Review Pharmacology & Pharmacy

Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome

Yahiya Y. Syed

Summary: Ravulizumab is a humanized monoclonal antibody indicated for the treatment of aHUS, with a convenient maintenance dosage regimen compared to eculizumab, and has shown good efficacy and tolerability in clinical trials.

DRUGS (2021)

Add to Collection

Review Medicine, General & Internal

Interventions for atypical haemolytic uraemic syndrome

Dan Pugh, Eoin D. O'Sullivan, Fiona Ai Duthie, Philip Masson, David Kavanagh

Summary: AHUS is a rare disorder characterized by abnormal complement regulatory proteins, leading to kidney failure and death in the past. However, new therapies such as terminal complement inhibition show promising outcomes, although based on very low-quality evidence from single-arm studies. Careful consideration of future data is needed for better understanding of treatment duration and adverse outcomes.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Review Medicine, General & Internal

Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome syndrome

Aamer Imdad, Samuel P. Mackoff, David M. Urciuoli, Tamkeenat Syed, Emily E. Tanner-Smith, Dongmei Huang, Oscar G. Gomez-Duarte

Summary: This review evaluated evidence on secondary preventative strategies for HUS associated with STEC infections, finding uncertainty in the effectiveness and safety of interventions to prevent development of HUS in patients with diarrhoea due to STEC infection. Additional studies, including larger multicentre studies, are needed to draw firm conclusions about the efficacy of these interventions.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Urology & Nephrology

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal

Caroline Duineveld, Romy Bouwmeester, Joost W. van der Heijden, Stefan P. Berger, Nicole C. A. J. van de Kar, Jack F. M. Wetzels

Summary: This interim analysis evaluated the safety of re-treatment with eculizumab in 11 patients with suspected relapse. Results showed that re-treatment with eculizumab after relapse is safe. Transplanted patients responded better to eculizumab therapy compared to those with aHUS in native kidneys.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Immunology

Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies

Gautier Breville, Ido Zamberg, Salima Sadallah, Caroline Stephan, Belen Ponte, Jorg D. Seebach

Summary: This study describes the potential pathogenic role of Ig4 autoantibodies in complement-mediated thrombotic microangiopathy in a patient with IgG4-related disease. The patient was successfully treated with plasmapheresis, corticosteroids, and cyclophosphamide, achieving remission. The results suggest a link between genetic predispositions such as CFHR1 and CFHR4 gene deletions and the formation of inhibitory anti-Factor H IgG4 antibodies.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Urology & Nephrology

A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report

Muneera Alabdulqader, Khalid Alfakeeh

Summary: Atypical haemolytic uraemic syndrome (aHUS) is a rare systemic syndrome characterized by non-immune haemolytic anaemia, thrombocytopenia, and kidney injury, with most cases caused by alternative complement pathway dysregulation. However, a mutation in the diacylglycerol kinase epsilon (DGKE) gene can also lead to aHUS, theoretically affecting the coagulation pathway instead of the complement pathway. Limited data is available for the management of these patients, and ideal treatment protocols have not yet been established.

BMC NEPHROLOGY (2021)

Add to Collection

Review Urology & Nephrology

Haemolytic uraemic syndrome associated with pancreatids: report of four cases and review of the literature

Justo Sandino-Perez, Eduardo Gutierrez, Fernando Caravaca-Fontan, Enrique Morales, Lucia Aubert-Girbal, Ramon Delgado-Lillo, Manuel Praga

Summary: This study identified four cases of HUS following acute pancreatitis, with a mean age of 30 years and all patients being male, primarily due to excessive alcohol consumption. All patients developed progressive AKI shortly after pancreatitis onset, requiring kidney replacement therapy, but eventually showed good recovery. One patient treated with eculizumab had a faster recovery compared to others.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Immunology

Anti-factor H antibody and its role in atypical hemolytic uremic syndrome

Rupesh Raina, Guneive Mangat, Gordon Hong, Raghav Shah, Nikhil Nair, Brian Abboud, Sumedha Bagga, Sidharth Kumar Sethi

Summary: Atypical hemolytic uremic syndrome (aHUS) is an important form of thrombotic microangiopathy (TMA) that often leads to acute kidney injury (AKI). Anti-factor H associated aHUS is a specific subtype of aHUS caused by complement factor H gene deletions and the presence of anti-factor H antibodies. However, not all patients with this subtype have the CFHR1/R3 deletion. Dysregulation of the complement system, particularly the alternative pathway, due to factor H dysfunction can result in inflammatory or autoimmune diseases. Treatment options such as plasma exchange therapy, Eculizumab, and immunosuppressants have shown positive effects in patients with this disease. Further advancements in the diagnosis and management of anti-factor H associated aHUS are needed due to its genetic predisposition.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Transplantation

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan

Shuichi Ito, Hiroshi Hataya, Akira Ashida, Riku Hamada, Tomoaki Ishikawa, Yumiko Ishikawa, Akihiko Shimono, Takao Konomoto, Tomoki Miyazawa, Masao Ogura, Kazuki Tanaka, Shoji Kagami

Summary: Eculizumab demonstrated good efficacy and tolerability in pediatric patients with aHUS in a real-world setting in Japan. The treatment led to significant improvements in platelet count, lactate dehydrogenase, and estimated glomerular filtration rate, and achieved complete TMA response, hematologic normalization, and sCr decrease in a high percentage of patients.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Add to Collection

Article Urology & Nephrology

Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study

Jose Portoles, Ana Huerta, Emilia Arjona, Eva Gavela, Marisa Aguera, Carlos Jimenez, Teresa Cavero, Domingo Marrero, Santiago Rodriguez de Cordoba, Fritz Diekmann

Summary: Both pre-aHUS and de novo patients showed different clinical profiles and responses to ECU treatment. Genetic studies are important in determining risks of relapse and guiding treatment decisions. ECU may be considered as a preemptive treatment for patients at moderate or high risk of recurrence.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Urology & Nephrology

Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis

Jingnan Feng, Ke Xu, Xinmiao Shi, Lu Xu, Lili Liu, Fang Wang, Xuhui Zhong, Guozhen Liu, Jinxi Wang, Pei Gao, Jie Ding, Shengfeng Wang, Siyan Zhan

Summary: This study provides the first population-based data on the incidence of HUS in urban China. The age and seasonal distributions of HUS in urban China differ from those in most developed countries, indicating a difference in etiology. The average medical cost of HUS per patient is significantly higher than the national average for all inpatients in the same period.

BMC NEPHROLOGY (2022)

Add to Collection

Article Immunology

Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia

Douwe Jan Dijkstra, A. Inkeri Lokki, Lobke Marijn Gierman, Nicole Veronique Borggreven, Carin van der Keur, Michael Eikmans, Kyra Andrea Gelderman, Hannele Laivuori, Ann-Charlotte FINNPEC Core Investigator Grp, Ann-Charlotte Iversen, Marie-Louise P. van der Hoorn, Leendert Adrianus Trouw

Summary: Preeclampsia (PE) may be associated with decreased levels of C1q and FH, which are related to placental dysfunction and immune response.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination

Taylor S. Cohen, Elizabeth J. Kelly, Sven Nylander, Himanshu Bansal, Brett M. Jepson, Prakash Bhuyan, Magdalena E. Sobieszczyk, Ann R. Falsey

Summary: Rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported after AZD1222 vaccination. A study analyzed anti-PF4 levels in paired samples from a phase 3 trial of AZD1222 vs placebo. The results indicate that AZD1222 does not induce a clinically relevant general increase in anti-PF4 IgG.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Medicine, General & Internal

Detection and Prediction of Macrophage Activation Syndrome in Still's Disease

Clement Javaux, Thomas El-Jammal, Pierre-Antoine Neau, Nicolas Fournier, Mathieu Gerfaud-Valentin, Laurent Perard, Marine Fouillet-Desjonqueres, Julie Le Scanff, Emmanuelle Vignot, Stephane Durupt, Arnaud Hot, Alexandre Belot, Isabelle Durieu, Thomas Henry, Pascal Seve, Yvan Jamilloux

Summary: Distinguishing between macrophage activation syndrome (MAS) and a simple flare of Still's disease (SD) may be challenging. This study aimed to clarify the clinical features and outcome of MAS in SD and explore predictive factors for MAS development.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Rheumatology

JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

Louise Gillard, Jacques Pouchot, Fleur Cohen-Aubart, Isabelle Kone-Paut, Gael Mouterde, Martin Michaud, Heloise Reumaux, Lea Savey, Alexandre Belot, Bruno Fautrel, Stephane Mitrovic

Summary: JAKi agents can be considered as a therapeutic option for difficult-to-treat Still's disease, especially for patients with partial response to medium- or high-dose corticosteroids or biologics.

RHEUMATOLOGY (2023)

Add to Collection

Editorial Material Pediatrics

Diagnostic dilemma in a 3-year-old girl with acute nephritic syndrome and hematologic abnormalities: Questions

Samantha Innocenti, Silvia Bernardi, Maud Prevot, Antonin Saldmann, Maud Tusseau, Alexandre Belot, Jean-Paul Duong Van Huyen, Olivia Boyer

PEDIATRIC NEPHROLOGY (2023)

Add to Collection

Editorial Material Pediatrics

Diagnostic dilemma in a 3-year-old girl with acute nephritic syndrome and hematologic abnormalities: Answers

Samantha Innocenti, Silvia Bernardi, Maud Prevot, Antonin Saldmann, Maud Tusseau, Alexandre Belot, Jean-Paul Duong Van Huyen, Olivia Boyer

PEDIATRIC NEPHROLOGY (2023)

Add to Collection

Meeting Abstract Rheumatology

JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS: A STUDY OF 69 CASES

Djohra Hadef, Samy Slimani, Mohamed Choukri Khamari, Walid Mekaoussi, Alexandre Belot, Pierre Quartier

RHEUMATOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Rescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review

Franck Zekre, Anita Duncan, Audrey Laurent, Maud Tusseau, Remi Pescarmona, Sophie Collardeau-Frachon, Camille Ohlmann, Sebastien Viel, Philippe Reix, Sarah Benezech, Alexandre Belot

Summary: Biological disease-modifying anti-rheumatic drugs (bDMARDs) targeting IL-6 and IL-1 beta are commonly used as a first-line therapy for systemic-onset juvenile idiopathic arthritis (sJIA), but they may increase the risk of pulmonary alveolar proteinosis (PAP). We report a new case of PAP-MAS successfully treated with Janus Kinase inhibitors (JAKi) and review previous clinical descriptions of this condition. Among the analyzed articles, the incidence of PAP-MAS among sJIA patients ranged from 1.28% to 12.9%. JAKi shows promise in treating lung disease associated with sJIA.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Evaluation and Management of Deficiency of Adenosine Deaminase 2 An International Consensus Statement

Pui Y. Lee, Brad A. Davidson, Roshini S. Abraham, Blanche Alter, Juan I. Arostegui, Katherine Bell, Alexandre Belot, Jenna R. E. Bergerson, Timothy J. Bernard, Paul A. Brogan, Yackov Berkun, Natalie T. Deuitch, Dimana Dimitrova, Sophie A. Georgin-Lavialle, Marco Gattorno, Bodo Grimbacher, Hasan Hashem, Michael S. Hershfield, Rebecca N. Ichord, Kazushi Izawa, Jennifer A. Kanakry, Raju P. Khubchandani, Femke C. C. Klouwer, Evan A. Luton, Ada W. Man, Isabelle Meyts, Joris M. Van Montfrans, Seza Ozen, Janna Saarela, Gustavo C. Santo, Aman Sharma, Ariane Soldatos, Rachel Sparks, Troy R. Torgerson, Ignacio Leandro Uriarte, Taryn A. B. Youngstein, Qing Zhou, Ivona Aksentijevich, Daniel L. Kastner, Eugene P. Chambers, Amanda K. Ombrello

Summary: Deficiency of adenosine deaminase 2 (DADA2) is a recessively inherited disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency affecting both children and adults. This study provides consensus statements for the evaluation and management of DADA2, a potentially fatal disease that requires early diagnosis and treatment.

JAMA NETWORK OPEN (2023)

Add to Collection

Editorial Material Rheumatology

Assessment of type I interferon response in routine practice in France in 2022

Anais Nombel, Anne Perrine Foray, Lorna Garnier, Christine Lombard, Eric Hachulla, Brigitte Bader-Meunier, Sophie Georgin-Lavialle, Isabelle Melki, Thierry Walzer, Alexandre Belot, Sebastien Viel

Summary: An European Alliance of Associations for Rheumatology task force has suggested specific considerations for studying the type I interferon pathway, noting the lack of validated assays for clinical use. In this report, we present the French experience of using a type I interferon pathway assay routinely since 2018 in Lyon, France.

RMD OPEN (2023)

Add to Collection

Article Pediatrics

Clinics dedicated to transition preparation for adolescents and young adults with chronic conditions: Factors influencing their use

Enora Le Roux, Aurelie Bourmaud, Paul Jacquin, Nizar Mahlaoui, Aurelien Guffroyf, Alexandre Belot, Melanie Romier, Jane Sattoe, Anneloes Van Staa, Corinne Alberti, Helene Mellerioa, Agnes Dumasa

Summary: To address inequalities in access to transition preparation for patients, transition clinics were established in France. However, despite their existence, the care departments in hospitals, which needed the most support for transition preparation, did not fully adopt these clinics. A strategy is required to improve the adoption of transition clinics and reduce inequalities.

ARCHIVES DE PEDIATRIE (2023)

Add to Collection

Article Immunology

Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI Syndrome

Kenza Rhzioual Berrada, Alexandre Belot, Benedicte Neven, Camille Ohlmann, Francois Tronc, Gillian Rice, Guillaume Thouvenin, Jean-Christophe Dubus, Julie Mazenq, Marie-Louise Fremond, Nathalie Stremler, Severine Soummer-Feuillet, Vincent Cottin, Philippe Reix

Summary: STING-associated vasculopathy with onset in infancy (SAVI) is a rare autoinflammatory disease characterized by fever attacks and skin and respiratory manifestations. Respiratory involvement occurs in 80% of cases and may require lung transplantation. Three patients with SAVI who underwent lung transplantation have been reported, but their diagnosis was made after transplantation, preventing targeted therapy.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

Add to Collection

Review Immunology

Phenotypic Variability in PRKCD: a Review of the Literature

Lucy Jefferson, Athimalaipet Vaidyanathan Ramanan, Stephen Jolles, Jolanta Bernatoniene, Anne-Laure Mathieu, Alexandre Belot, Marion Ruth Roderick

Summary: This article reviews the current data on the pathophysiology, clinical presentation, investigation and management of PKC delta deficiency. Twenty cases have been described in the literature with significant heterogeneity.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Athimalaipet Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller

Summary: Baricitinib demonstrated good efficacy and acceptable safety in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.

LANCET (2023)

Add to Collection

Article Rheumatology

Extra-osseous manifestations in chronic recurrent multifocal osteomyelitis: a retrospective study

Marie Robert, Anna Giolito, Heloise Reumaux, Linda Rossi-Semerano, Claire Guillemin, Louis Biarrotte, Damia Leguevaques, Alexandre Belot, Agnes Duquesne, Cecile Frachette, Audrey Laurent, Marine Desjonqueres, Jean-Paul Larbre, Caroline Galeotti, Isabelle Kone-Paut, Perrine Dusser

Summary: This study aimed to investigate the frequency, characteristics and treatment of extra-osseous (EO) manifestations in chronic recurrent multifocal osteomyelitis (CRMO) and whether different phenotypes can benefit from special management. The study included 133 CRMO patients and found that 67.7% of them had EO manifestations, primarily skin lesions, sacroiliitis, enthesitis, arthritis, and gastrointestinal manifestations. Patients with EO manifestations were more likely to be treated with biologics, and a significant number of them achieved complete remission under this treatment.

RHEUMATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

Danye Lee, Jeremie Le Pen, Ahmad Yatim, Beihua Dong, Yann Aquino, Masato Ogishi, Remi Pescarmona, Estelle Talouarn, Darawan Rinchai, Peng Zhang, Magali Perret, Zhiyong Liu, Iolanda Jordan, Sefika Elmas Bozdemir, Gulsum Iclal Bayhan, Camille Beaufils, Lucy Bizien, Aurelie Bisiaux, Weite Lei, Milena Hasan, Jie Chen, Christina Gaughan, Abhishek Asthana, Valentina Libri, Joseph M. Luna, Fabrice Jaffre, H. -Heinrich Hoffmann, Eleftherios Michailidis, Marion Moreews, Yoann Seeleuthner, Kaya Bilguvar, Shrikant Mane, Carlos Flores, Yu Zhang, Andres A. Arias, Rasheed Bailey, Agatha Schlueter, Baptiste Milisavljevic, Benedetta Bigio, Tom Le Voyer, Marie Materna, Adrian Gervais, Marcela Moncada-Velez, Francesca Pala, Tomi Lazarov, Romain Levy, Anna-Lena Neehus, Jeremie Rosain, Jessica Peel, Yi-Hao Chan, Marie-Paule Morin, Rosa Maria Pino-Ramirez, Serkan Belkaya, Lazaro Lorenzo, Jordi Anton, Selket Delafontaine, Julie Toubiana, Fanny Bajolle, Victoria Furnado, Marta L. DeDiego, Nadhira Fidouh, Flore Rozenberg, Jordi Perez-Tur, Shuibing Chen, Todd Evans, Frederic Geissmann, Pierre Lebon, Susan R. Weiss, Damien Bonnet, Xavier Duval, Qiang Pan-Hammarstroem, Anna M. Planas, Isabelle Meyts, Filomeen Haerynck, Aurora Pujol, Vanessa Sancho-Shimizu, Clifford L. Dalgard, Jacinta Bustamante, Anne Puel, Stephanie Boisson-Dupuis, Bertrand Boisson, Tom Maniatis, Qian Zhang, Paul Bastard, Luigi Notarangelo, Vivien Beziat, Rebeca Perez de Diego, Carlos Rodriguez-Gallego, Helen C. Su, Richard P. Lifton, Emmanuelle Jouanguy, Aurelie Cobat, Laia Alsina, Sevgi Keles, Elie Haddad, Laurent Abel, Alexandre Belot, Lluis Quintana-Murci, Charles M. Rice, Robert H. Silverman, Shen-Ying Zhang, Jean-Laurent Casanova

SCIENCE (2023)

Add to Collection

Article Rheumatology

Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial

Duvuru Geetha, Anisha Dua, Huibin Yue, Jason Springer, Carlo Salvarani, David Jayne, Peter Merkel

Summary: This study evaluated the efficacy and safety of avacopan in a subgroup of patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis receiving rituximab as background induction therapy. The results showed that avacopan was comparable to prednisone taper in achieving remission at week 26, but had greater efficacy at week 52. Additionally, avacopan was associated with improved renal outcomes and lower glucocorticoid toxicity.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.